Unlock stock picks and a broker-level newsfeed that powers Wall Street.

HKSE - Delayed Quote HKD

FUSEN PHARM (1652.HK)

0.260
+0.005
+(1.96%)
At close: 2:17:15 PM GMT+8

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.
NameTitlePayExercisedYear Born
Mr. Zhiming Cao CEO & Executive Chairman 5.32M -- 1986
Mr. Taisheng Hou Executive Director 86.2k -- 1963
Mr. Yongsheng Chi Executive Director 83.01k -- 1962
Ms. Qingfen Meng Executive Director 65.98k -- 1965
Mr. Zhen Li Chief Financial Officer -- -- 1978
Mr. Yuk Hong Yeung Company Secretary -- -- 1991

FUSEN PHARM

Urban Industrial Zone
Xichuan County
Nanyang
China
https://www.fusenyy.com
Sector: 
Healthcare
Full Time Employees: 
1,131

Description

Fusen Pharmaceutical Company Limited, an investment holding company, researches and develops, manufactures, and sells pharmaceutical products in the People's Republic of China. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; heat-clearing and detoxicating oral solutions; nicardipine hydrochloride injections; and other products. It also offers cardio cerebrovascular, blood pressure and sugar reduction, tonifying, qi-regulating, anti-anemia, antibacterial and anti-inflammatory, gastrointestinal tract, and expectorant cough category products. It also researches, develops, produces, and sells various proprietary Chinese medicines and western medicine products for the treatment of cold, fever, cardiovascular diseases, and anemia. In addition, the company offers business management and consulting services; and engages in the sale of construction material and electricity. Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.

Corporate Governance

FUSEN PHARM’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

March 31, 2025 at 2:52 PM UTC

FUSEN PHARM Earnings Date

Recent Events

June 7, 2022 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers